Member Info for Laura2022

Sorry for your losses on DDDD porky

You've not posted anything positive on val or pyc but nothing but QBT

Please keep to your own discussion groups

From the PYC Q and A which clearly addresses why PYC can rarely put values

Q: Is there any particular reason for the value of contracts remaining undisclosed?

We can’t always disclose both the identity of our client and the value of the contract because they won’t let us.  In my view, it’s more important for our shareholders and other stakeholders to understand who it is that we’re working with and what we’re doing rather than announce that we have a contract with an undisclosed pharmaceutical or biotech Company, because that sort of announcement never feels very satisfying and generally means that we can’t then really talk in any detail about what we’re doing with that client.   I believe the value of being able to disclose the identity of clients is greater than the value of just disclosing the contract size.  Where we’re required to disclose for reasons of compliance with regulations, then then we do so.

If all or most of the pipeline were won it would be double the revenues received last year

Pipeline: Discussions ongoing with over 25 largely new potential clients regarding projects with an estimated total value of over £1.5m which could be commenced in financial year 2024.

In order to further develop its business and accelerate growth, the Company is raising funds to carry out activities including:

· Further expansion and diversification of its client base;

· Expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and

· Exploration of opportunities around its personalised oncology software 

Thankyou Msuk

As you say,2 in 2 days and looks like the future is very bright

 awarded a further contract by existing client, Numab Therapeutics ("Numab"). The project involves PKPD modelling in support of one of Numab's clinical programs and follows on from earlier work conducted by Physiomics on the same asset. The project will span two years of the clinical program.

 

There was no delayed trade yesterday for the 1dt time in 2 weeks

Whatever has been worked in the background been done....the buys amounte to more than 10% of the company so they were either forward sold shares (illegal) or a background buyer

One of the worst was DDDD apparently

They committed daylight robbery of shareholders and wasted £millions

Director buys confirmed

Thankyou Kidlington

Gunsup

Looks like those large trades could be directors ones .?

Does anyone know who this company is tha that the bio labs ?

Collaborative Services Agreement

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, announces the signature of a Collaborative Services Agreement with ValiRx's wholly owned subsidiary Inaphaea BioLabs Limited.

The agreement recognises the synergy between Inaphaea's growing capabilities as a translational contract research organisation (tCRO®) providing in-vitro laboratory-based services and Physiomics' in-silico capabilities for advanced statistical analyses, machine learning techniques, data handling and visualisation, as well as biological modelling.

Toffee

I agree,at £1.2mln cap and £800k cash with a recent "substantial " contract with a client who have raised $250mln last month it makes PYC incredibly undervalued and I would think more contracts will will come

a takeover from an A.I company or an existing client is also a possibly

Have you invested Toffee?

Sienna

Please contact the company if you have some thoughts

Info@physiomics.

Nice buying now

Imho apta and pyc go next

AI shares beyond 'Big Tech'

Healthcare, capital goods, payments and financial exchanges can all benefit from artificial intelligence

There is only £1000 available to buy on HL

Article over the weekend in an investment magazine

PYC fits the narrative

A shot in the arm for healthcare?

AI techniques are already being applied in healthcare, specifically in the medical devices, services and life sciences branches of the industry. And in fields such as testing and diagnostics, where the highest degree of accuracy is required, non-AI solutions can be greatly improved upon. One note of caution is that companies using AI in this space could find themselves competing with technology giants, Google Health being a prime example.

That said, there is hardly a shortage of niches in healthcare research and services, so companies with expertise to build on could capitalise despite big tech’s creeping influence. Oncology testing is one such area and the cancer research programmes of Guardant Health (US:GH) will be buoyed by its partnership with South Korea’s Lunit (KR:328130) and the launch of an AI-based suite of products: Guardant Galaxy.

Now commercially available, a new test for non-small cell lung cancer improves detection by more than 20 per cent. The Lunit-developed, AI-powered algorithm boost the ability of medical image analytics to detect cancer biomarkers (molecules, genes or characteristics)

Morning Gun

Think this will continue to increase

Very many thanks for that Kidlington